Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07017270
PHASE4

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Sponsor: Unity Health Toronto

View on ClinicalTrials.gov

Summary

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-07

Completion Date

2027-09

Last Updated

2025-06-12

Healthy Volunteers

No

Interventions

DRUG

Semaglutide Pen

Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.

Locations (1)

Unity Health Toronto

Toronto, Ontario, Canada